Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is well-positioned for growth and success in the healthcare industry due to their diverse portfolio, successful new product launches, and strong performance in their Innovative Medicine division. With a focus on key therapeutic areas and strategic plans for continued growth, JNJ has the potential to become a top oncology company by 2030 and continue to expand through M&A and innovation. However, potential risks such as new product launches and macro issues should be closely monitored. Additionally, JNJ's long history and presence in critical therapeutic areas make them a stable and reliable investment choice.

Bears say

Johnson & Johnson is facing several challenges that may impact its future growth potential and financial performance. These include potential difficulties in its pharmaceutical pipeline gaining traction, the risk of losing patent exclusivity for certain drugs, and ongoing legal disputes related to its talc products. Additionally, the recent divestment of its consumer business may result in slower growth as it focuses solely on healthcare. These concerns, along with a potential decline in sales from its MedTech division, contribute to a negative outlook on the stock.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $260.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $260.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.